MCM
DNLI icon

Masters Capital Management’s Denali Therapeutics DNLI Stock Holding History

Masters Capital Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.5M Sell
600,000
-400,000
-40% -$7.96M 0.38% 57
2025
Q4 		$16.5M Buy
1,000,000
+250,000
+33% +$4.22M 0.67% 47
2025
Q3 		$10.9M Buy
750,000
+150,000
+25% +$2.16M 0.39% 55
2025
Q2 		$8.39M Buy
+600,000
New +$8.45M 0.33% 53

Other funds holding DNLI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Masters Capital Management's DNLI Position: Q1 2026 in Review

Masters Capital Management reduced its Denali Therapeutics (DNLI) stake by 40% in Q1 2026, selling an estimated $7.96M and leaving 600,000 shares worth $11.5M. The position accounts for 0.38% of the portfolio, ranked #57.

Masters Capital Management first reported a position in DNLI in Q2 2025 and has held it in 4 quarters since. The position peaked at $16.5M in Q4 2025. 269 funds tracked by Wall St. Rank hold DNLI as of Q1 2026.

  • Masters Capital Management held 600,000 shares of Denali Therapeutics worth $11.5M as of Q1 2026.
  • Masters Capital Management sold 400,000 Denali Therapeutics shares in Q1 2026, an estimated $7.96M.
  • Denali Therapeutics made up 0.38% of Masters Capital Management's portfolio in Q1 2026, its #57 holding.
  • Masters Capital Management first reported a position in Denali Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Masters Capital Management's Denali Therapeutics position peaked at $16.5M in Q4 2025.
  • 269 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2026.

Based on Masters Capital Management's 13F filing for Q1 2026, filed 15 May 2026.